تحميل...
Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study
BACKGROUND: Abiraterone acetate was introduced in Quebec in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who had received chemotherapy with docetaxel. This study describes abiraterone use in the early postapproval period and its clinical effectiveness...
محفوظ في:
| الحاوية / القاعدة: | CMAJ Open |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Joule Inc. or its licensors
2017
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5378527/ https://ncbi.nlm.nih.gov/pubmed/28401143 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9778/cmajo.20160082 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|